The Trump administration is working to significantly expand veterans’ access to psychedelic drugs for treating post-traumatic stress disorder (PTSD) and depression. An estimated 2.1 million veterans may benefit from such treatments, including psilocybin from magic mushrooms or MDMA, according to Andrew Gradison, a senior adviser at the Veterans Health Administration. Currently, about 6.4 million veterans depend on the Department of Veterans Affairs (VA) for healthcare.
For some veterans, PTSD affects sleep, relationships, safety, and self-image after deployment.
Christopher DiViaio, clinical director at Eleve Behavioral Health, highlights the interest in exploring alternatives like psychedelic-assisted therapy because traditional treatments like therapy and medication do not work for everyone.
Federal regulators have yet to approve psychedelic drugs as safe and effective treatments for mental health conditions, posing significant practical and safety challenges for the VA even if treatments gain approval.
Why It Matters
Veterans are central to potential psychedelic treatment strategies, especially as new approaches to PTSD and other mental health issues are researched. President Donald Trump issued an executive order in April to expedite research, clinical trials, and patient access to psychedelic therapies.
The U.S. Food and Drug Administration (FDA) has not yet approved psychedelic therapies for these conditions, and under the Biden administration, it rejected MDMA combined with therapy as a PTSD treatment in 2024.
What to Know
Gradison spoke about expanding psychedelic treatments during the Horizons: Perspectives on Psychedelics conference in New York City. He aims to enhance the VA’s capacity to offer such therapies to about one-third of regular VA patients with mental health conditions, translating to up to 2.1 million veterans.
The VA is fully supporting the initiative, preparing sites and logistics for a rapid rollout.
Toby Marton, chief medical officer at Radial Health and former VA psychiatrist, indicates the VA is investing resources into 20 psychedelic clinical trials. Despite preparations, Gradison noted challenges in treating patients at scale due to practical and safety considerations.
The administration seeks to accelerate regulatory and research processes for eventual legal availability of pharmaceutical treatments to VA patients.
This effort is driven by the veteran lobby due to existing treatments’ limitations for conditions tied to military service.
The VA’s participation in clinical trials aligns with Trump’s executive order, which spotlighted ibogaine as a potential treatment. Despite its Schedule I controlled substance status, Trump cited veteran suicide as a national tragedy, believing psychedelic treatments might have substantial benefits.
Psychedelic Drugs Face FDA Hurdles
A significant question remains: Can these treatments secure FDA approval? The FDA’s 2024 rejection of MDMA with therapy for PTSD marks a setback. However, regulatory measures aim to hasten the development of other psychedelic therapies, with fast-track review for three companies, including Compass Pathways developing synthetic psilocybin for depression.
Even with approval, the VA’s challenge lies in providing safe, widespread treatment to interested veterans.
Psychedelic therapy excites due to veterans’ prolonged suffering, but it requires careful presentation and assessment.
DiViaio underscores the need for identifying those who benefit, managing risks, and providing adequate support before, during, and after treatment.
What Happens Next
If the FDA approves these therapies, the Trump administration will face challenges in implementing treatments within the VA. DiViaio emphasizes the need for evidence and safeguards, affordability, access to trained professionals, and follow-up care to ensure accessibility beyond clinical trials.
Newsweek produced this story using Martyn, an AI assistant.

Mayor Mamdani’s Policing Reform Plans
Gen Z Voter Shifts and Their Impact on the 2026 Midterm Elections
Disappearance of US Senate Candidate Raises Questions
DOJ Rule Change Reduces Appeal Time for Immigrants Facing Deportation
Hakeem Jeffries’ Bid for House Speaker Faces Progressive Hurdles
Ohio Judge Dismisses Defamation Lawsuit by Rep. Max Miller